There are no studies which have compared the risk of severe COVID‐19 and related mortality
between transplant recipients and nontransplant patients. We enrolled two groups of …

Notwithstanding the ongoing coronavirus disease-2019 (Covid-19) pandemic, information
on its clinical presentation and prognosis in recipients of a kidney transplant remain scanty. …

1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19
vaccine. N Engl J Med. 2020; 383: 2603-2615. 2. Baden LR, El Sahly HM, Essink B, et al. …

End stage kidney disease increase the risk of COVID-19 related death but how the kidney
replacement strategy should be adapted during the pandemic is unknown. Chronic …

The aim of this study (ClinicalTrials.gov, NCT01744470) was to determine the efficacy and
safety of two different doses of extended-release tacrolimus (TacER) in kidney transplant …

Background Atypical hemolytic uremic syndrome (HUS) is associated with high recurrence
rates after kidney transplant, with devastating outcomes. In late 2011, experts in France …

Background Belatacept (bela) rescue therapy seems to be a valuable option for calcineurin
inhibitor chronic toxicity in kidney transplantation. Nevertheless, the risk of infection …

Pretransplantation adaptation of the daily dose of tacrolimus to CYP3A5 genotype is
associated with improved achievement of target trough concentration (C 0 ), but whether this …

Background Rituximab has shown encouraging results for the treatment of kidney transplantation
recipients with focal segmental glomerulosclerosis (FSGS) recurrence. However, the …

Introduction Kidney transplant recipients (KTRs) are prone to develop severe COVID-19
and are less well protected by vaccine than immunocompetent subjects. Thus, the use of …